Biomerica Inc Revenue Growth Rates (BMRA), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Biomerica Inc   (NASDAQ: BMRA)
 

BMRA's Revenue Growth by Quarter and Year

Biomerica Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/BMRA/growth
https://api.csimarket.com/api/v1/companies/BMRA/fundamentals
https://api.csimarket.com/api/v1/companies/BMRA/fundamentals?mode=as_of&as_of=YYYY-MM-DD
Programmatic access for models, analytics, and integration workflows.
Explore the Financial Data API
Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery
Connect Your AI Assistant
How to Connect Your AI Assistant to CSIMarket MCP MCP Server
Access this full dataset via API
Free sample Full docs All endpoints
BMRA Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter May -
3rd Quarter February -
2nd Quarter November -
1st Quarter August 1.27
FY 1.27

BMRAs Annual Revenue
Biomerica Inc 's Revenue in the fiscal year 2026 $ 4.45 millions
Biomerica Inc 's Revenue in the fiscal year 2025 $ 5.31 millions
Biomerica Inc 's Revenue in the fiscal year 2024 $ 5.42 millions
Biomerica Inc 's Revenue in the fiscal year 2023 $ 5.34 millions
Biomerica Inc 's Revenue in the fiscal year 2022 $ 18.87 millions




BMRA Revenue first quarter 2026 Y/Y Growth Comment
Biomerica Inc reported decrease in Revenue in the first quarter 2026 by -8.33% to $ 1.27 millions, from the same quarter in 2025.
The decrease in the first quarter 2026 Biomerica Inc 's Revenue compares unfavorably to the Company's average Revenue increase of 13.75%.

Looking into first quarter 2026 results within In Vitro & In Vivo Diagnostic Substances industry 8 other companies have achieved higher Revenue growth. While Biomerica Inc ' s Revenue decline of -8.33% ranks overall at the positon no. 3341 in the first quarter 2026.


BMRA Revenue ( Y/Y Growth %) 2026
 FY 2025 FY 2024 FY 2023
4th Quarter May -
3rd Quarter February -
2nd Quarter November -
1st Quarter August -8.33 %
FY   -

Financial Statements
Biomerica Inc 's first quarter 2026 Revenue $ 1.27 millions BMRA's Income Statement
Biomerica Inc 's first quarter 2025 Revenue $ 1.38 millions Quarterly BMRA's Income Statement


BMRA Revenue (Quarter on Quarter Growth %)

 2026
 FY 2025 FY 2024 FY 2023
4th Quarter May -
3rd Quarter February -
2nd Quarter November -
1st Quarter August 43.75 %
FY (Year on Year)   -


Back to BMRA Growth rate Comparisons >> Back to BMRA Growth rate Comparisons >>


Revenue first quarter 2026 Y/Y Growth Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry #9
Healthcare Sector #452
Overall #3341

Revenue Y/Y Growth Statistics
High Average Low
403.01 % 13.75 % -85.49 %
 
Revenue first quarter 2026 Y/Y Growth Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry #9
Healthcare Sector #452
Overall #3341
Revenue Y/Y Growth Statistics
High Average Low
403.01 % 13.75 % -85.49 %
 

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Biomerica Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
268.28 % 8.77 % -70.95 %
(Nov 30 2021)  


BMRA's I. Quarter Q/Q Revenue Comment
Biomerica Inc achieved in the I. Quarter 2026 above company average sequential Revenue jump of 43.75%, to $ 1.27 millions, from $0.88 millions in the fourth quarter.

Within In Vitro & In Vivo Diagnostic Substances industry Biomerica Inc achieved highest sequential Revenue growth. While Biomerica Inc 's Revenue growth quarter on quarter, overall rank is 281.


Revenue Q/Q Growth Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry #1
Healthcare Sector #73
Overall #281
Revenue Q/Q Growth Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry #1
Healthcare Sector #73
Overall #281
Revenue Q/Q Growth Statistics
High Average Low
268.28 % 8.77 % -70.95 %
(Nov 30 2021)  


BMRA's I. Quarter Q/Q Revenue Comment
Biomerica Inc achieved in the I. Quarter 2026 above company average sequential Revenue jump of 43.75%, to $ 1.27 millions, from $0.88 millions in the fourth quarter.

Within In Vitro & In Vivo Diagnostic Substances industry Biomerica Inc achieved highest sequential Revenue growth. While Biomerica Inc 's Revenue growth quarter on quarter, overall rank is 281.


Biomerica Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Aug 31 2026)		 12 Months Ending (May 31 2026) 12 Months Ending (Feb 28 2026) 12 Months Ending (Nov 30 2025) 12 Months Ending (Aug 31 2025)
Cumulative Revenue 12 Months Ending $ 4.34
Y / Y Revenue Growth (TTM) -11.18 %
Year on Year Revenue Growth Overall Ranking # 3510
Seqeuential Revenue Change (TTM) -2.58 %
Seq. Revenue Growth (TTM) Overall Ranking # 3510


Cumulative Revenue growth Comment
Biomerica Inc showed decline, but improvement compare to trailing twelve month Revenue decrease in May 31 2026. If the fiscal year would end in Aug 31 2026, Biomerica Inc 's annual Revenue decline would be -11.18% year on year to $4 millions.

In the Healthcare sector 428 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 3510, from total ranking in previous quarter at 4046.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry # 10
Healthcare Sector # 429
Overall # 3267

Revenue TTM Y/Y Growth Statistics
High Average Low
163.05 %
 5.67 %
-71.87 %
(Aug 31 2022)  


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 10
Sector # 423
S&P 500 # 3158
Cumulative Revenue growth Comment
Biomerica Inc showed decline, but improvement compare to trailing twelve month Revenue decrease in May 31 2026. If the fiscal year would end in Aug 31 2026, Biomerica Inc 's annual Revenue drop would be -11.18% year on year to $4 millions.

In the Healthcare sector 428 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 3510, from total ranking in previous quarter at 4046.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry # 10
Healthcare Sector # 429
Overall # 3267

Revenue TTM Y/Y Growth Statistics
High Average Low
163.05 %
5.67 %
-71.87 %
(Aug 31 2022)  


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 10
Sector # 423
S&P 500 # 3158




Other Revenue Growth
In Vitro & In Vivo Diagnostic Substances Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
BMRA's Revenue Growth Ratio versus In Vitro & In Vivo Diagnostic Substances Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue drop for the quarter ending Aug 31 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Aug 31 2026
Cryo cell International Inc -0.02%$ -0.016 millions
Medinotec Inc -1.10%$ -1.103 millions
Biomerica Inc -8.33%$ -8.333 millions


About Biomerica Inc Revenue Growth Rates (BMRA), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Biomerica Inc (CIK 73290).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001493152-26-047271
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Biomerica Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.